CLARITY News and Research

RSS

The lipid-exchanged, anatomically rigid, imaging/immunostaining compatible, tissue hydrogel (CLARITY) method was initially designed in 2013 by Chung and Deisseroth at the Stanford University School of Medicine. Using this process, post-mortem organs can be labeled for proteins and nucleic acids, enabling analysis of intact samples to create detailed 3D images.

Data of focusing on Rebif and Cladribine Tablets to be presented at AAN Annual Meeting

EMD Serono, Inc., an affiliate of Merck KGaA, Darmstadt, Germany, today announced that new data from the company's multiple sclerosis portfolio of approved and investigational treatments will be presented at the 62nd Annual Meeting of the American Academy of Neurology taking place April 10 to 17, in Toronto, Canada.

1 Apr 2010

Repros Therapeutics announces response to FDA critique on proposed Phase II Androxal study

Repros Therapeutics Inc. today announced that the Company is sending a reply to the FDA's Division of Metabolism and Endocrinology Products following the Company's receipt of FDA's comments on the proposed Phase II study of Androxal® (enclomiphene) in the treatment of Type II diabetes under Repros' open IND. On February 2, 2010 the Company announced that Repros received confirmation from the Agency that the new IND is effective.

1 Apr 2010

Facts and treatment options for endometriosis

One out of every two women struggling to conceive may suffer from endometriosis - the leading cause of infertility - according to research from Camran Nezhat, M.D., gynecologist at El Camino Hospital, the hospital of the Silicon Valley.

31 Mar 2010

iPhone can provide valuable assistance to insurance holders

Mobile devices such as the iPhone can provide valuable assistance to insurance holders in a claims situation, comparison site Constructaquote.com has said.

29 Mar 2010

New CONSORT statement to improve reporting of trial findings published

New guidance to improve the reporting of trial findings is published simultaneously today (24 March 2010) by PLoS Medicine and eight other leading journals around the world, BMJ, The Lancet, Obstetrics & Gynecology, Annals of Internal Medicine, Open Medicine, Journal of Clinical Epidemiology, BMC Medicine, and Trials.

26 Mar 2010

FDA approves Riverain Medical's Softview Enhanced Chest Imaging technology

Riverain Medical, a leading image enhancement and computer-aided detection company dedicated to providing physicians with tools to assist in image interpretation, announced today that the U.S. Food and Drug Administration (FDA) has cleared the SoftView Enhanced Chest Imaging technology.

25 Mar 2010

Nabi Biopharmaceuticals expands share repurchase program to enhance shareholder value

Nabi Biopharmaceuticals announced today that its Board of Directors has approved an aggregate total of up to $60.9 million to repurchase the Company's outstanding common shares in the open market or in privately negotiated transactions.

24 Mar 2010

First Edition: March 22, 2010

Today's headlines detail yesterday's historic House vote on health reform while also looking forward to how action might play out in the Senate, how the legislative package impacts the current political dynamic and what its effects will be on consumers and stakeholders.

22 Mar 2010

Surgeon General to outline priorities at PCPCC Stakeholder's Summit

Surgeon General Regina Benjamin, MD, knows first-hand the connection doctors and patients need in order to address tough chronic health threats. Benjamin will discuss her priorities as Surgeon General in a keynote address at the Stakeholder's Summit of the Patient-Centered Primary Care Collaborative (PCPCC) at 10 a.m. on March 30 in Washington, DC.

22 Mar 2010

The Purpose Institute to support Healthways' Vitality Quest initiative

Healthways, Inc., a Founding Member of The Purpose Institute, announced today that that the Institute has been engaged to support the Company’s recently announced Vitality QuestSM initiative to help communities committed to the health, well-being and productivity of their citizens become Healthways-Blue Zones Vitality CitiesSM

22 Mar 2010

Atritech to initiate confirmatory study of WATCHMAN LAA Closure Device

Atritech, Inc., an emerging medical device company, announced today that it has obtained clarity from the U.S. Food and Drug Agency on the regulatory path towards full approval of its WATCHMAN® Left Atrial Appendage Closure Technology in the United States.

19 Mar 2010

AstraZeneca's CRESTOR: Health Canada approves new indication

AstraZeneca announced today that Health Canada has approved CRESTOR (rosuvastatin calcium) to reduce the risk of nonfatal myocardial infarction (heart attack), nonfatal stroke, and coronary artery revascularization in adult patients without documented history of cardiovascular or cerebrovascular events, but with at least two conventional risk factors for cardiovascular disease.

17 Mar 2010

Acucela, Otsuka Pharmaceutical granted FDA Fast Track designation for ACU-4429 in treatment of dry AMD

Acucela Inc., a clinical-stage biotechnology company focused on developing new treatments for blinding eye diseases, and Otsuka Pharmaceutical Co., Ltd., today announced that they have received Fast Track designation from the U.S. Food and Drug Administration (FDA) for ACU-4429, an investigational oral treatment for dry age-related macular degeneration (dry AMD).

17 Mar 2010

AstraZeneca Canada's IRESSA receives approval for treatment of NSCLC

AstraZeneca Canada announces the recently approved indication for IRESSA(R), a once-daily oral targeted therapy for the first-line treatment of patients with locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) who have activating mutations of the epidermal growth factor receptor-tyrosine kinase (EGFR-TK). In conjunction with this approval, AstraZeneca is also announcing the availability of a diagnostic test which can now determine a patient's EGFR mutation status, representing a new era in personalized lung cancer treatment in Canada.

17 Mar 2010

Toshiba displays new, advanced ultrasound systems at ACC annual meeting

Health care facilities use ultrasound as a first-line diagnostic exam to quickly and efficiently perform a range of patient exams, including cardiac imaging. Developed to meet these demanding clinical needs, Toshiba America Medical Systems, Inc. will showcase the advanced cardiac capabilities of its AplioTM MX and Aplio ArtidaTM ultrasound systems at this year’s American College of Cardiology (ACC) annual meeting in Atlanta, March 14-16, 2010 (Booth #1944). This is the first appearance of the Aplio MX at ACC.

16 Mar 2010

FDA provides guidance on Restanza clinical program in treatment of CABP

Advanced Life Sciences Holdings, Inc., a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, oncology and respiratory diseases, announced today that the U.S. Food and Drug Administration has provided guidance on the clinical program required to assess the approvability of Restanza™ (cethromycin), a novel oral once-a-day antibiotic, in the treatment of outpatient community acquired bacterial pneumonia (CABP) as well as biodefense indications including anthrax, plague and tularemia.

11 Mar 2010

ADI’s 20-bit DAC enables superior image clarity, resolution, and contrast in medical imaging systems

MRI (magnetic resonance imaging) scans provide extraordinarily clear images of the human body and are commonly used to diagnose a wide range of illnesses and injuries, such as Alzheimer’s disease, cancerous tumors, and torn ligaments. Analog Devices, Inc., the leading provider of data conversion technology and longtime collaborator with the medical imaging industry, today introduced a breakthrough in data conversion that gives clinicians and radiologists the superior image clarity they need to see smaller anatomical structures and abnormalities, such as breast cancer cells, than ever before.

11 Mar 2010

Antibacterial activity of clay minerals raises hope for natural approaches to antibacterial cures

Alternative approaches to medicine are stock-in-trade in the ASU laboratory of microbiologist Shelley Haydel.

6 Mar 2010

CIGNA's Explanation of Benefits earns “Excellent” designation for Clarity, Content and Design

Health service company CIGNA has earned the top ranking among national health plans for the industry’s key customer communication, the Explanation of Benefits. CIGNA's Explanation of Benefits is one of only three to earn an “Excellent” designation for Clarity, Content and Design in an evaluation by DALBAR, Inc.

5 Mar 2010

P&R Dental Strategies develops and builds Rapid Review Imaging System for digitizing x-ray images

After nearly two decades building her company into the industry leader for third-party review of dental insurance claims, Dianne Rose, D.D.S., and principal of P&R Dental Strategies, Inc., was frustrated. In spite of many advances over the years in both dental x-ray technologies and the average quality of images supplied for review of dental claims, there was no consistency and, all-too-often, regardless of how up-to-date the x-ray equipment being used may have been, the images supplied were blurred and nearly useless for making accurate diagnostic determinations.

4 Mar 2010

CLARITY News and Research

Further Reading

Data of focusing on Rebif and Cladribine Tablets to be presented at AAN Annual Meeting

Repros Therapeutics announces response to FDA critique on proposed Phase II Androxal study

Facts and treatment options for endometriosis

iPhone can provide valuable assistance to insurance holders

New CONSORT statement to improve reporting of trial findings published

FDA approves Riverain Medical's Softview Enhanced Chest Imaging technology

Nabi Biopharmaceuticals expands share repurchase program to enhance shareholder value

First Edition: March 22, 2010

Surgeon General to outline priorities at PCPCC Stakeholder's Summit

The Purpose Institute to support Healthways' Vitality Quest initiative

Atritech to initiate confirmatory study of WATCHMAN LAA Closure Device

AstraZeneca's CRESTOR: Health Canada approves new indication

Acucela, Otsuka Pharmaceutical granted FDA Fast Track designation for ACU-4429 in treatment of dry AMD

AstraZeneca Canada's IRESSA receives approval for treatment of NSCLC

Toshiba displays new, advanced ultrasound systems at ACC annual meeting

FDA provides guidance on Restanza clinical program in treatment of CABP

ADI’s 20-bit DAC enables superior image clarity, resolution, and contrast in medical imaging systems

Antibacterial activity of clay minerals raises hope for natural approaches to antibacterial cures

CIGNA's Explanation of Benefits earns “Excellent” designation for Clarity, Content and Design

P&R Dental Strategies develops and builds Rapid Review Imaging System for digitizing x-ray images

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest Life Science News